These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 30467000)

  • 21. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.
    Marty FM; Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Oren I; Schmitt-Hoffmann AH; Giladi M; Rahav G; Perfect JR
    Mycoses; 2018 Jul; 61(7):485-497. PubMed ID: 29611227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
    Ananda-Rajah MR; Kontoyiannis D
    Future Microbiol; 2015; 10(5):693-708. PubMed ID: 26000646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
    Jenks JD; Salzer HJ; Prattes J; Krause R; Buchheidt D; Hoenigl M
    Drug Des Devel Ther; 2018; 12():1033-1044. PubMed ID: 29750016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis.
    Zhang J; Zhang Y; Wu D; Cao G; Hamed K; Desai A; Aram JA; Guo X; Fayyad R; Cornely OA
    Mycoses; 2021 Apr; 64(4):445-456. PubMed ID: 33355949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
    Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
    Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant.
    Alexander BD; Perfect JR; Daly JS; Restrepo A; Tobón AM; Patino H; Hardalo CJ; Graybill JR
    Transplantation; 2008 Sep; 86(6):791-6. PubMed ID: 18813103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.
    Rybak JM; Marx KR; Nishimoto AT; Rogers PD
    Pharmacotherapy; 2015 Nov; 35(11):1037-51. PubMed ID: 26598096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.
    Desai AV; Kovanda LL; Hope WW; Andes D; Mouton JW; Kowalski DL; Townsend RW; Mujais S; Bonate PL
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Invasive mould infections in the ICU setting: complexities and solutions.
    Bassetti M; Bouza E
    J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i39-i47. PubMed ID: 28355466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.
    Wu X; Venkataramanan R; Rivosecchi RM; Tang C; Marini RV; Shields RK; Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials.
    Durand ML; Kitt TM; Song Y; Marty FM
    Clin Infect Dis; 2021 Sep; 73(6):e1380-e1383. PubMed ID: 33914864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological management of invasive mold infections in solid organ transplant recipients.
    Fernández-Ruiz M
    Expert Opin Pharmacother; 2024 Feb; 25(3):239-254. PubMed ID: 38436619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isavuconazole: Case Report and Pharmacokinetic Considerations.
    Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P
    Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
    McCarthy MW; Moriyama B; Petraitiene R; Walsh TJ; Petraitis V
    Clin Pharmacokinet; 2018 Dec; 57(12):1483-1491. PubMed ID: 29725999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
    Marty FM; Ostrosky-Zeichner L; Cornely OA; Mullane KM; Perfect JR; Thompson GR; Alangaden GJ; Brown JM; Fredricks DN; Heinz WJ; Herbrecht R; Klimko N; Klyasova G; Maertens JA; Melinkeri SR; Oren I; Pappas PG; Ráčil Z; Rahav G; Santos R; Schwartz S; Vehreschild JJ; Young JH; Chetchotisakd P; Jaruratanasirikul S; Kanj SS; Engelhardt M; Kaufhold A; Ito M; Lee M; Sasse C; Maher RM; Zeiher B; Vehreschild MJGT;
    Lancet Infect Dis; 2016 Jul; 16(7):828-837. PubMed ID: 26969258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of Aspergillus fumigatus sternal osteomyelitis with isavuconazole in a heart transplant recipient.
    Assaf A; Faure E; Sermet K; Loridant S; Leroy J; Goeminne C; Dozier A; Chopin MC; Panaget S; Faure K; Vuotto F
    Transpl Infect Dis; 2020 Oct; 22(5):e13313. PubMed ID: 32386273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.
    Desai A; Kovanda L; Kowalski D; Lu Q; Townsend R; Bonate PL
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5483-91. PubMed ID: 27381396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plain language summary: use of isavuconazole in Chinese patients with an invasive fungal disease.
    Zhang J; Zhang Y; Wu D; Cao G; Hamed K; Desai A; Aram JA; Guo X; Fayyad R; Cornely OA
    Future Microbiol; 2022 Oct; 17():1203-1206. PubMed ID: 35916057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pharmacokinetic challenge of treating invasive aspergillosis complicating severe influenzae assisted by extracorporeal membrane oxygenation.
    Winiszewski H; Rougny AC; Lagoutte-Renosi J; Millon L; Capellier G; Navellou JC; Piton G; Clairet AL
    Crit Care; 2018 Dec; 22(1):355. PubMed ID: 30577863
    [No Abstract]   [Full Text] [Related]  

  • 40. Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study.
    Thompson GR; Garcia-Diaz J; Miceli MH; Nguyen MH; Ostrosky-Zeichner L; Young JH; Fisher CE; Clark NM; Greenberg RN; Spec A; Kovanda L; Croos-Dabrera R; Kontoyiannis DP
    Mycoses; 2022 Feb; 65(2):186-198. PubMed ID: 34888961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.